Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Inflammatory Bowel Diseases

  Free Subscription


22.11.2021

2 Aliment Pharmacol Ther
3 Am J Gastroenterol
1 BMC Gastroenterol
2 Dis Colon Rectum
1 Eur J Gastroenterol Hepatol
1 Gastroenterol Hepatol
2 Gastroenterology
4 Gut
14 Inflamm Bowel Dis
13 J Crohns Colitis
1 J Immunol
1 J Pediatr
6 Lancet Gastroenterol Hepatol
2 Scand J Gastroenterol


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Aliment Pharmacol Ther

  1. MESERVE J, Singh S
    Editorial: risk of pneumonia in IBD-reading between the lines!
    Aliment Pharmacol Ther. 2021;54.
    PubMed        

  2. HAMDEH S, Micic D, Hanauer S
    Review article: drug-induced small bowel injury.
    Aliment Pharmacol Ther. 2021;54.
    PubMed         Abstract available


    Am J Gastroenterol

  3. CALDERA F, Knutson KL, Saha S, Wald A, et al
    Humoral Immunogenicity of mRNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease and Healthy Controls.
    Am J Gastroenterol. 2021 Nov 18. pii: 00000434-990000000-00148.
    PubMed         Abstract available

  4. MELMED GY, Oliver B, Hou JK, Lum D, et al
    Quality of Care Program Reduces Unplanned Health Care Utilization in Patients With Inflammatory Bowel Disease.
    Am J Gastroenterol. 2021 Nov 19. pii: 00000434-990000000-00153.
    PubMed         Abstract available

  5. BRUNT H, Chapman JC
    The Inflammatory Bowel Disease-Focused Primary Care Provider: An Addition to the IBD Specialty Medical Home.
    Am J Gastroenterol. 2021 Nov 17. pii: 00000434-990000000-00144.
    PubMed        


    BMC Gastroenterol

  6. FUJITA Y, Tominaga K, Tanaka T, Sugaya T, et al
    Ulcerative colitis relapse after Helicobacter pylori eradication in a 12-year-old boy with duodenal ulcer.
    BMC Gastroenterol. 2021;21:424.
    PubMed         Abstract available


    Dis Colon Rectum

  7. WANG K, Huang L, Huang W, Liu R, et al
    The Predictive Value of Computed Tomography Enterography Index for Postoperative Intra-Abdominal Septic Complications in Patients with Crohn's Disease: Implications for Surgical Decision Making.
    Dis Colon Rectum. 2021 Apr 26. pii: 00003453-900000000-99487.
    PubMed         Abstract available

  8. MYRELID P, Kalman TD
    Old, New, and Out of the Box in IBD Surgery: Proceedings of the European Crohn's and Colitis Organisation 2020 Congress From a Surgical Perspective.
    Dis Colon Rectum. 2021;64:929-931.
    PubMed        


    Eur J Gastroenterol Hepatol

  9. ADEGBOLA SO, Sarafian M, Sahnan K, Ding NS, et al
    Differences in amino acid and lipid metabolism distinguish Crohn's from idiopathic/cryptoglandular perianal fistulas by tissue metabonomic profiling and may offer clues to underlying pathogenesis.
    Eur J Gastroenterol Hepatol. 2021;33:1469-1479.
    PubMed         Abstract available


    Gastroenterol Hepatol

  10. JULIAO-BANOS F, Arrubla M, Osorio L, Camargo J, et al
    Characterization and prevalence of extraintestinal manifestations in a cohort of patients with inflammatory intestinal disease in Medellin, Colombia.
    Gastroenterol Hepatol. 2021;44:398-404.
    PubMed         Abstract available


    Gastroenterology

  11. BOLTON C, Smillie CS, Pandey S, Elmentaite R, et al
    An integrated taxonomy for monogenic inflammatory bowel disease.
    Gastroenterology. 2021 Nov 12. pii: S0016-5085(21)03737.
    PubMed         Abstract available

  12. DI NARZO AF, Houten SM, Kosoy R, Huang R, et al
    Integrative analysis of the Inflammatory Bowel Disease serum metabolome improves our understanding of genetic etiology and points to novel putative therapeutic targets.
    Gastroenterology. 2021 Nov 12. pii: S0016-5085(21)03738.
    PubMed         Abstract available


    Gut

  13. MCGREGOR CG, Adams A, Sadler R, Arancibia-Carcamo CV, et al
    Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic.
    Gut. 2021;70:2398-2400.
    PubMed        

  14. AXELRAD JE, Olen O, Sachs MC, Erichsen R, et al
    Reply: Survival in Crohn's disease-associated small bowel adenocarcinoma.
    Gut. 2021;70:998.
    PubMed        

  15. GIUFFRIDA P, Vanoli A, Di Sabatino A
    Survival in Crohn's disease-associated small bowel adenocarcinoma.
    Gut. 2021;70:997-998.
    PubMed        

  16. ZHAO R, Wan QY, Wu Y, Wang Y, et al
    Crohn's disease instead of UC might increase the risk of small bowel cancer.
    Gut. 2021;70:809-810.
    PubMed        


    Inflamm Bowel Dis

  17. CHICCO F, Magri S, Cingolani A, Paduano D, et al
    Multidimensional Impact of Mediterranean Diet on IBD Patients.
    Inflamm Bowel Dis. 2021;27:1-9.
    PubMed         Abstract available

  18. CALDERA F, Ley D, Hayney MS, Farraye FA, et al
    Optimizing Immunization Strategies in Patients with IBD.
    Inflamm Bowel Dis. 2021;27:123-133.
    PubMed         Abstract available

  19. ARVANITIS M, Hart LC, DeWalt DA, Diaz-Gonzalez de Ferris ME, et al
    Transition Readiness Not Associated With Measures of Health in Youth With IBD.
    Inflamm Bowel Dis. 2021;27:49-57.
    PubMed         Abstract available

  20. SZIGETHY E, Murphy SM, Ehrlich OG, Engel-Nitz NM, et al
    Mental Health Costs of Inflammatory Bowel Diseases.
    Inflamm Bowel Dis. 2021;27:40-48.
    PubMed         Abstract available

  21. SEGAL JP, Askari A, Clark SK, Hart AL, et al
    The Incidence and Prevalence of Human Papilloma Virus-associated Cancers in IBD.
    Inflamm Bowel Dis. 2021;27:34-39.
    PubMed         Abstract available

  22. VASSEUR P, Dugelay E, Benamouzig R, Savoye G, et al
    Dietary Patterns, Ultra-processed Food, and the Risk of Inflammatory Bowel Diseases in the NutriNet-Sante Cohort.
    Inflamm Bowel Dis. 2021;27:65-73.
    PubMed         Abstract available

  23. OLAISEN M, Flatberg A, Granlund AVB, Royset ES, et al
    Bacterial Mucosa-associated Microbiome in Inflamed and Proximal Noninflamed Ileum of Patients With Crohn's Disease.
    Inflamm Bowel Dis. 2021;27:12-24.
    PubMed         Abstract available

  24. RIPOLLES T, Poza J, Suarez Ferrer C, Martinez-Perez MJ, et al
    Evaluation of Crohn's Disease Activity: Development of an Ultrasound Score in a Multicenter Study.
    Inflamm Bowel Dis. 2021;27:145-154.
    PubMed         Abstract available

  25. WESTBERG K, Olen O, Soderling J, Bengtsson J, et al
    Primary Versus Staged Reconstruction and Risk of Surgical Failure in Patients With Ulcerative Colitis: a Nation-wide Cohort Study.
    Inflamm Bowel Dis. 2021 Nov 18. pii: 6430979. doi: 10.1093.
    PubMed         Abstract available

  26. SACHAN A, Singh AK
    Reply to Response to "Strongyloides stercoralis in Acute Severe Ulcerative Colitis-A Triggering Nuisance or an Opportunistic Bystander?" by Hokama et al.
    Inflamm Bowel Dis. 2021 Nov 15. pii: 6428578. doi: 10.1093.
    PubMed        

  27. HANZEL J, Dreesen E, Vermeire S, Lowenberg M, et al
    Corrigendum to: Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients with Crohn Disease: Posthoc Analysis of the LOVE-CD Study.
    Inflamm Bowel Dis. 2021 Nov 12. pii: 6426108. doi: 10.1093.
    PubMed        

  28. HOKAMA A, Fujita J
    Response to "Strongyloides stercoralis in Acute Severe Ulcerative Colitis-A Triggering Nuisance or an Opportunistic Bystander?"
    Inflamm Bowel Dis. 2021 Nov 12. pii: 6426022. doi: 10.1093.
    PubMed        

  29. PENRICE DD, Kamboj AK, Simonetto DA
    Infliximab-induced Liver Injury: A Common Link Between Crohn's Disease and Acute Liver Injury.
    Inflamm Bowel Dis. 2021;27:e7-e8.
    PubMed        

  30. REINISCH W, Gecse K, Halfvarson J, Irving PM, et al
    Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease.
    Inflamm Bowel Dis. 2021;27:106-122.
    PubMed         Abstract available


    J Crohns Colitis

  31. LOCHHEAD P, Khalili H, Sachs MC, Chan AT, et al
    Association Between Statin Use and Inflammatory Bowel Diseases: Results from a Swedish, Nationwide, Population-based Case-control Study.
    J Crohns Colitis. 2021;15:757-765.
    PubMed         Abstract available

  32. KLANG E, Grinman A, Soffer S, Margalit Yehuda R, et al
    Automated Detection of Crohn's Disease Intestinal Strictures on Capsule Endoscopy Images Using Deep Neural Networks.
    J Crohns Colitis. 2021;15:749-756.
    PubMed         Abstract available

  33. MOTTA JP, Palese S, Giorgio C, Chapman K, et al
    Increased Mucosal Thrombin is Associated with Crohn's Disease and Causes Inflammatory Damage through Protease-activated Receptors Activation.
    J Crohns Colitis. 2021;15:787-799.
    PubMed         Abstract available

  34. NELSON A, Stewart CJ, Kennedy NA, Lodge JK, et al
    The Impact of NOD2 Genetic Variants on the Gut Mycobiota in Crohn's Disease Patients in Remission and in Individuals Without Gastrointestinal Inflammation.
    J Crohns Colitis. 2021;15:800-812.
    PubMed         Abstract available

  35. VERSTOCKT B, Pouillon L, Bossuyt P
    Tofacitinib and Subacute Pneumonitis: Don't Hold Your Breath.
    J Crohns Colitis. 2021;15:692-693.
    PubMed        

  36. RUTKA M, Pigniczki D, Molnar T
    Tofacitinib Therapy, the Lender of Last Resort.
    J Crohns Colitis. 2021;15:694.
    PubMed        

  37. MULLER M, D'Amico F, Bonovas S, Danese S, et al
    TNF Inhibitors and Risk of Malignancy in Patients with Inflammatory Bowel Diseases: A Systematic Review.
    J Crohns Colitis. 2021;15:840-859.
    PubMed         Abstract available

  38. ASHTON JJ, Boukas K, Davies J, Stafford IS, et al
    Ileal Transcriptomic Analysis in Paediatric Crohn's Disease Reveals IL17- and NOD-signalling Expression Signatures in Treatment-naive Patients and Identifies Epithelial Cells Driving Differentially Expressed Genes.
    J Crohns Colitis. 2021;15:774-786.
    PubMed         Abstract available

  39. DAI C, Jiang M, Huang YH
    Association Between Statin Use and Inflammatory Bowel Diseases.
    J Crohns Colitis. 2021;15:1246.
    PubMed        

  40. NICHOLSON MR, Alexander E, Ballal S, Davidovics Z, et al
    Efficacy and Outcomes of Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection in Children with Inflammatory Bowel Disease.
    J Crohns Colitis. 2021 Nov 12. pii: 6425925. doi: 10.1093.
    PubMed         Abstract available

  41. GUPTA R, MacIsaac M, Wright EK
    Sleeve gastrectomy in patients with inflammatory bowel disease is not associated with worsening disease.
    J Crohns Colitis. 2021 Nov 17. pii: 6430439. doi: 10.1093.
    PubMed        

  42. D'AMICO F, Magro F, Peyrin-Biroulet L, Danese S, et al
    Positioning filgotinib in the treatment algorithm of moderate to severe ulcerative colitis.
    J Crohns Colitis. 2021 Nov 16. pii: 6429427. doi: 10.1093.
    PubMed         Abstract available

  43. BACSUR P, Farkas K, Molnar T
    Outcome of immediate dose optimization of infliximab in inflammatory bowel disease patients.
    J Crohns Colitis. 2021 Nov 18. pii: 6430840. doi: 10.1093.
    PubMed        


    J Immunol

  44. BHAUMIK S, Mickael ME, Moran M, Spell M, et al
    RORgammat Promotes Foxp3 Expression by Antagonizing the Effector Program in Colonic Regulatory T Cells.
    J Immunol. 2021;207:2027-2038.
    PubMed         Abstract available


    J Pediatr

  45. DEJONG NA, Wofford M, Song PH, Kappelman MD, et al
    Association of Care Coordination Experience and Health Services Use with Main Provider Type for Children with Inflammatory Bowel Disease.
    J Pediatr. 2021;234:142-148.
    PubMed         Abstract available


    Lancet Gastroenterol Hepatol

  46. PEYRIN-BIROULET L, Hart A, Bossuyt P, Long M, et al
    Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
    Lancet Gastroenterol Hepatol. 2021 Nov 16. pii: S2468-1253(21)00298.
    PubMed         Abstract available

  47. DANESE S, Colombel JF, Lukas M, Gisbert JP, et al
    Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.
    Lancet Gastroenterol Hepatol. 2021 Nov 16. pii: S2468-1253(21)00294.
    PubMed         Abstract available

  48. VERMEIRE S, Lakatos PL, Ritter T, Hanauer S, et al
    Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.
    Lancet Gastroenterol Hepatol. 2021 Nov 16. pii: S2468-1253(21)00295.
    PubMed         Abstract available

  49. RUBIN DT, Dotan I, DuVall A, Bouhnik Y, et al
    Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.
    Lancet Gastroenterol Hepatol. 2021 Nov 16. pii: S2468-1253(21)00338.
    PubMed         Abstract available

  50. AGRAWAL M, Verstockt B
    Etrolizumab for ulcerative colitis: beyond what meets the eye.
    Lancet Gastroenterol Hepatol. 2021 Nov 16. pii: S2468-1253(21)00369.
    PubMed        

  51. MOURAD FH, Hashash JG
    Inflammatory bowel disease in Lebanon: a plea for help.
    Lancet Gastroenterol Hepatol. 2021 Nov 11. pii: S2468-1253(21)00390.
    PubMed        


    Scand J Gastroenterol

  52. CHRISTENSEN KR, Steenholdt C, Buhl S, Brynskov J, et al
    A systematic monitoring approach to biologic therapies in inflammatory bowel disease: patients' and physicians' preferences and adherence.
    Scand J Gastroenterol. 2021 Nov 13:1-8. doi: 10.1080/00365521.2021.2002397.
    PubMed         Abstract available

  53. FURUYA Y, Fukai K, Nakazawa S, Kojimahara N, et al
    Occupational physical activity differentially affects the risk for developing later-onset Crohn's disease and ulcerative colitis among middle-aged and older populations.
    Scand J Gastroenterol. 2021 Nov 11:1-8. doi: 10.1080/00365521.2021.1999495.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: